logo

Von Willebrand Disease Treatment Market Size (2024 - 2029)

The Von Willebrand disease treatment market is anticipated to experience significant growth over the forecast period, driven by factors such as increased patient assistance programs and rising healthcare expenditure. The COVID-19 pandemic has notably influenced the market, creating opportunities for treatment availability due to the correlation between elevated von Willebrand factor levels and worse COVID-19 outcomes. The growing incidence and prevalence of VWD globally are prompting the development of new drugs and therapies, further contributing to market expansion. Despite these positive trends, challenges such as a lack of awareness and high treatment costs may impede market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Genetic Disorder Drugs Research Von Willebrand Disease Treatment Market Market Size

Market Size of Von Willebrand Disease Treatment Industry

Von Willebrand Disease Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR (2024 - 2029) 6.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Von Willebrand Disease Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Von Willebrand Disease Treatment Market Analysis

The Von Willebrand Disease Treatment Market is expected to register a CAGR of 6.5% during the forecast period.

Factors such as a rise in patient assistance programs and increasing healthcare expenditure worldwide are expected to fuel the market's growth during the forecast period.

The incidence and prevalence of VWD disease are increasing globally and creating new opportunities for developing new drugs, therapies, and treatments in the market. For instance, according to the CDC in May 2024, Von Willebrand disease (VWD) affects approximately 1% of the general population, with men and women equally susceptible. However, due to the heightened bleeding it triggers, women often exhibit more pronounced VWD symptoms, especially during menstruation, pregnancy, and post-childbirth. From 2012 to 2023, over 33,456 individuals, encompassing men, women, and children, sought treatment for VWD at hemophilia treatment centers. Notably, nearly two-thirds of these patients were women and girls. Thus, the high burden of VWD is expected to increase demand for novel therapies, including novel clotting factors and other medications entering the market, expanding the treatment options available, thereby boosting market growth.

In addition, as per a research study published in the Journal of Blood Medicine in March 2023, approximately 0.6-1.3% of the general population was affected by VWD, and the prevalence of symptomatic VWD was approximately 10 per 100,000 during the study period of the research. This growing disease burden is attracting the focus of government bodies and market players toward investments and the development of innovative drugs, contributing to market growth. Thus, the market is expected to grow over the forecast period due to the abovementioned factors.

The strategic initiatives taken by market players, such as product launches and mergers and acquisitions, are expected to contribute to market growth over the forecast period. For instance, in April 2022, Octapharma, a key player in the healthcare industry, secured the prestigious title of Gold Sponsor for the World Federation of Haemophilia (WFH) 2022 World Congress, scheduled from May 8 to 11, 2022. At the event, Octapharma announced plans to shed light on the critical unmet needs faced by individuals grappling with Von Willebrand disease (VWD) through a live symposium. Similarly, in January 2022, Takeda secured FDA approval in the United States for VONVENDI, a recombinant Von Willebrand factor, for patients with severe type 3 Von Willebrand disease, specifically for routine prophylaxis alongside on-demand therapy.

Thus, all the aforementioned factors, such as the growing burden of VWD and strategic initiatives taken by market players, are expected to boost market growth over the forecast period. However, the need for more awareness and the high cost of treatment are the factors hindering market growth.

Von Willebrand Disease Treatment Industry Segmentation

As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by a missing or defective Von Willebrand factor (VWF), a clotting protein.

The Von Willebrand disease treatment market is segmented by disease type, treatment type, route of administration, and geography. By disease type, the market is segmented into type 1, type 2, type 3, and acquired VMD. By treatment type, the market is segmented into desmopressin, replacement therapies, clot-stabilizing medication, and other treatment types. By route of administration, the market is segmented into oral, injection, and other routes of administration. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in value (USD) for the above segments.

By Disease Type
Type 1
Type 2
Type 3
Acquired VWD
By Treatment Type
Desmopressin
Replacement Therapies
Clot-stabilizing Medications
Other Treatment Types
By Route of Administration
Oral
Injection
Other Routes of Administration
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Von Willebrand Disease Treatment Market Size Summary

The Von Willebrand disease (VWD) treatment market is poised for significant growth, driven by factors such as increased healthcare expenditure and patient assistance programs. The COVID-19 pandemic has notably impacted the market, as elevated levels of the von Willebrand factor antigen in COVID-19 patients have highlighted the need for effective VWD treatments. This has created opportunities for market expansion. The rising incidence and prevalence of VWD globally are prompting the development of new drugs and therapies, further fueling market growth. Despite challenges like high treatment costs and limited awareness, the market is expected to grow steadily, with replacement therapy emerging as a key segment due to its effective results and ongoing research.

North America holds a substantial share of the VWD treatment market, with the United States leading due to the high prevalence of the disease and the availability of innovative treatments. The region benefits from a focus on cost-effective drugs and strategic initiatives to raise awareness. The competitive landscape features major players like Bayer AG, CSL Behring, and Takeda, who are actively seeking product approvals to enhance their market presence. Recent approvals, such as the USFDA's endorsement of novel therapies, are expected to drive further growth. The market's expansion is supported by ongoing research and development, as well as initiatives to address unmet needs in VWD treatment.

Explore More

Von Willebrand Disease Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increase in Patient Assistance Programs

      2. 1.2.2 Growing Healthcare Expenditure

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness

      2. 1.3.2 High Costs of Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Disease Type

      1. 2.1.1 Type 1

      2. 2.1.2 Type 2

      3. 2.1.3 Type 3

      4. 2.1.4 Acquired VWD

    2. 2.2 By Treatment Type

      1. 2.2.1 Desmopressin

      2. 2.2.2 Replacement Therapies

      3. 2.2.3 Clot-stabilizing Medications

      4. 2.2.4 Other Treatment Types

    3. 2.3 By Route of Administration

      1. 2.3.1 Oral

      2. 2.3.2 Injection

      3. 2.3.3 Other Routes of Administration

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Von Willebrand Disease Treatment Market Size FAQs

The Von Willebrand Disease Treatment Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)

CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Ltd, Octapharma AG and Bio Products Laboratory Ltd. are the major companies operating in the Von Willebrand Disease Treatment Market.

Von Willebrand Disease Treatment Market Report Snapshots

Von Willebrand Disease Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)